title: Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
authors.affiliation: Departments of *Translational Hematology and Oncology Research, and†Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; ‡Department of Ophthalmic Oncology, Cole Eye Institute, and §Department of Molecular Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
authors.forename: Yan
authors.initials: Y
authors.lastname: Feng
authors.forename: Arun D
authors.initials: AD
authors.lastname: Singh
authors.forename: Christopher
authors.initials: C
authors.lastname: Lanigan
authors.forename: Raymond R
authors.initials: RR
authors.lastname: Tubbs
authors.forename: Patrick C
authors.initials: PC
authors.lastname: Ma
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077548:Anaplastic Lymphoma Kinase; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics*; D000077547:Crizotinib; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D050939:Gene Fusion; D015321:Gene Rearrangement; D006801:Humans; D007124:Immunoenzyme Techniques; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism*; D014178:Translocation, Genetic / Q000235:genetics
chemical_list: D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases